$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time
Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
HENDERSON, Nev. , April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the...
HENDERSON, Nev. , April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026,...
HENDERSON, Nev. , April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering...
Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time